Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective Randomized Trial

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Subarachnoid Hemorrhage
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Diagnosis of aneurysmal subarachnoid hemorrhage (aSAH).
    2. Able to start treatment with the investigational product (IP) within 96 hours from the onset of aSAH.
    3. If a woman of childbearing potential (WOCBP), must have a ne

You may not be eligible for this study if the following are true:

    1. Is at imminent risk of death and/or with Do Not Resuscitate (DNR) orders.
    2. Required cardiopulmonary resuscitation within 4 days prior to randomization.
    3. Has history of cirrhosis (Child-Pugh class B and C) prior to random

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.